Kickler T S
Johns Hopkins Medical Institutions, Baltimore, MD 21205.
Transfus Med Rev. 1990 Oct;4(4 Suppl 1):8-18. doi: 10.1016/s0887-7963(90)70237-4.
The limiting factor in platelet transfusion therapy is the development of alloimmunization. Although using HLA matched platelets may be effective in reducing the problem of alloimmune platelet transfusion refractoriness, relying solely upon HLA matching has its shortcomings. The selection of compatible platelet transfusions can be improved by compatibility testing. Despite these maneuvers, compatible platelets may not be found for some patients. When faced with these difficult patients there are few effective alternatives. The preventive measures of leukocyte depletion or ultraviolet irradiation of platelets promise to reduce or prevent alloimmunization.
血小板输注治疗中的限制因素是同种免疫的发生。虽然使用人类白细胞抗原(HLA)匹配的血小板可能有效地减少同种免疫性血小板输注无效的问题,但单纯依靠HLA匹配有其缺点。通过相容性检测可以改进相容性血小板输注的选择。尽管采取了这些措施,仍可能有一些患者找不到相容的血小板。面对这些棘手的患者,几乎没有有效的替代方法。血小板白细胞去除或紫外线照射的预防措施有望减少或防止同种免疫。